Skip to main content

Table 1 Demographic and clinical characteristics of patients with Acinetobacter baumannii bacteremic pneumonia stratified by 14-day mortality

From: Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia

Characteristics Survivors (n = 177) Non-survivors (n = 159) P-value
Demographics
 Male, No. (%) 128 (72.3) 122 (76.7) .36
 Age, median (IQR), years 70 (67–72) 69 (66–72) .64
 Acquired in ICU, No. (%) 91 (51.4) 90 (56.6) .34
 Previous ICU admission 127 (71.8) 110 (69.2) .61
 Length of hospitalization before bacteremia, median (IQR), days 36 (24–48) 35 (27–44) .98
Comorbidities, No. (%)
 Charlson co-morbidity score 3.8 (3.4–4.2) 3.9 (3.5–4.2) .75
  Malignancy 50 (28.3) 44 (27.7) .91
  Solid tumor 42 (23.7) 30 (18.9) .28
  Hematologic malignancy 8 (4.5) 21 (13.2) .005
 Type 2 diabetes mellitus 63 (35.6) 44 (27.7) .12
 Cerebrovascular accident 47 (26.6) 21 (13.2) .002
 Hypertension 85 (48.0) 65 (40.9) .19
 Immunosuppressant use 35 (19.8) 56 (35.2) .001
 Liver cirrhosis 19 (10.7) 14 (8.8) .55
 Chronic kidney disease 58 (32.8) 62 (39.0) .23
 Coronary artery disease 29 (16.4) 24 (15.1) .75
 Congestive heart failure 34 (19.2) 34 (21.4) .62
 Chronic obstructive pulmonary disease 39 (22.0) 33 (20.8) .78
 Collagen vascular disease 10 (5.7) 18 (11.3) .06
 Chemotherapy 13 (7.3) 21 (13.2) .08
 Neutropenia 8 (4.5) 13 (8.2) .17
 Recent surgery 64 (36.2) 32 (20.1) .001
Invasive procedures, No. (%)a
 Arterial line 63 (35.6) 69 (43.4) .14
 Central venous catheter 111 (62.7) 113 (71.1) .11
 Hemodialysis 21 (11.9) 26 (16.4) 024
 Tracheostomy 44 (24.9) 50 (31.5) .18
 Ventilator (previous use) 73 (41.2) 92 (57.9) .002
 Ventilator (current use) 121 (68.4) 121 (76.1) .12
 Ventilator associated pneumonia 121 (68.4) 113 (71.1) .59
Clinical condition
 APACHE II score within 24 h before bacteremia, median (IQR) 23 (21–24) 33 (32–35) <.001
 Shock 75 (42.4) 75 (47.2) .38
Resistance profiles of bloodstream isolates, No. (%)
 Multidrug resistance (MDR)b 156 (88.1) 150 (94.3) .046
 Carbapenem resistance 104 (58.8) 129 (81.1) <.001
 Extensive drug resistance (XDR)c 58 (32.8) 95 (59.8) <.001
Appropriate antimicrobial therapy 94 (53.1) 57 (35.9) .001
  1. Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, ICU intensive care unit, IQR interquartile range
  2. aAt the time the blood culture was obtained
  3. bResistance to at least one agent in at least three of the following classes of antimicrobials: antipseudomonal cephalosporins, antipseudomonal carbapenems, ampicillin-sulbactam, fluoroquinolones, and aminoglycosides
  4. cExtensive drug resistance (XDR) referred to non-susceptibility to imipenem or meropenem and all drug class except for colistin and tigecycline